Topline results were announced from a phase 2/3 trial evaluating #Linsitinib for the treatment of active, moderate to severe #ThyroidEyeDisease (TED).

Findings showed a statistically significant reduction in #Proptosis in the linsitinib 150mg twice daily group, with a proptosis responder rate of 52% at week 24.

Read here:#ClinicalTrial #Ophthalmology